Neurocrine Biosciences NBIX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's financing cash flow?
- Neurocrine Biosciences (NBIX) reported financing cash flow of -$86.1M in Q1 2026.
- How has Neurocrine Biosciences's financing cash flow changed year-over-year?
- Neurocrine Biosciences's financing cash flow increased by 27.0% year-over-year, from -$117.9M to -$86.1M.
- What is the long-term trend for Neurocrine Biosciences's financing cash flow?
- Over 2 years (2021 to 2024), Neurocrine Biosciences's financing cash flow has grown at a 332.7% compound annual growth rate (CAGR), from $27.4M to -$513.1M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.